News | Magnetic Resonance Imaging (MRI) | May 23, 2019

MRI Metal Artifact Reduction Poses Minimal Thermal Risk to Hip Arthroplasty Implants

Study results exhibited at 2019 ARRS Annual Meeting

MRI Metal Artifact Reduction Poses Minimal Thermal Risk to Hip Arthroplasty Implants

May 23, 2019 — Clinical metal artifact reduction sequence (MARS) magnetic resonance imaging (MRI) protocols at 3 Tesla (3T) on hip arthroplasty implants pose minimal risk of thermal injury, according to a recent study. The findings were presented at the American Roentgen Ray Society (ARRS) 2019 Annual Meeting, May 5-10 in Honolulu.

The study was conducted to investigate the heating effect of clinical and nonclinical MARS MRI protocols at 3T on different hip arthroplasty implants.

Two American Society for Testing and Materials (ASTM) MRI phantoms — objects developed to stand in for human tissue during MRI testing and calibration — were used to simulate the upper and lower portions of a human torso. Four total hip arthroplasty implant configurations were tested, including a metal-on-polyethylene construct with cobalt chromium (CoCr) femoral stem, a metal-on-metal construct with CoCr femoral stem, and two metal-on-ceramic constructs with titanium femoral stems at two lengths. Temperature changes of three clinical pulse sequence type protocols were measured, including high-bandwidth turbo spin echo (HBW-TSE), slice encoding for metal artifact correction (SEMAC) and compressed sensing SEMAC (CS-SEMAC). In addition, a 30-minute HBW sequence was modified twice to produce high, "supraclinical," SAR values to assess potential extreme scenarios.

The maximum heating at any single point was 1.9 °C across all three clinical MARS MRI protocols and implant configurations. With supraclinical high SAR pulse sequences at up to 30 min of continuous MRI, heating increased to 3.6 °C.

The results suggest only a minimal risk of thermal injury with the clinical MARS MRI protocols used, especially when adding the cooling effect of perfusion in physiologic conditions.

For more information: www.arrs.org

Related Content

ADHD Medication May Affect Brain Development in Children

Images of regions of interest (colored lines) in the white matter skeleton representation. Data from left and right anterior thalamic radiation (ATR) were averaged. Image courtesy of C. Bouziane et al.

News | Neuro Imaging | August 16, 2019
A drug used to treat attention-deficit/hyperactivity disorder (ADHD) appears to affect development of the brain’s...
Profound Medical Receives U.S. FDA 510(k) Clearance for Tulsa-Pro
Technology | Interventional Radiology | August 16, 2019
Profound Medical Corp. announced it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to...
Synaptive Medical Launches Modus Plan With Automated Tractography Segmentation
Technology | Neuro Imaging | August 07, 2019
Synaptive Medical announced the U.S. launch and availability of Modus Plan featuring BrightMatter AutoSeg. This release...
Canon Medical Introduces Encore Orian MR Upgrade Program
News | Magnetic Resonance Imaging (MRI) | August 06, 2019
Canon Medical Systems USA Inc. is helping to provide low-cost patient care solutions for its customers with the launch...
FDA Issues Draft Guidance on Medical Device Safety in MRI Environment
News | Magnetic Resonance Imaging (MRI) | August 01, 2019 | Jeff Zagoudis, Associate Editor
The U.S. Food and Drug Administration (FDA) issued a new draft guidance titled Testing and Labeling Medical Devices for...
Two brain metastases from primary lung cancer are contrast enhanced in the brain of a 61-year-old male. Speakers at AHRA 2019 will state that ProHance and other macrocyclic MR agents present a very low risk to patients. Images courtesy of Bracco

Two brain metastases from primary lung cancer are contrast enhanced in the brain of a 61-year-old male. Speakers at AHRA 2019 will state that ProHance and other macrocyclic MR agents present a very low risk to patients. Images courtesy of Bracco

Feature | Contrast Media | July 18, 2019 | By Greg Freiherr
Macrocyclic contrast agents have the best safety profile of all the magnetic resonance (MR) contrast media that are n
AAPM 2019 Features More Than 40 Presentations on ViewRay's MRIdian MRI-guided Radiotherapy
News | Image Guided Radiation Therapy (IGRT) | July 16, 2019
ViewRay Inc. announced that the company's MRIdian System is the focus of more than 40 abstracts selected by the...
FDA Approves Bayer's Gadavist Contrast for Cardiac MRI in Adult Coronary Artery Disease Patients
Technology | Contrast Media | July 15, 2019
The U.S. Food and Drug Administration (FDA) has approved Gadavist injection for use in cardiac magnetic resonance...
Insightec's Exablate Neuro Approved With GE Signa Premier MRI in U.S. and Europe
News | Focused Ultrasound Therapy | July 10, 2019
GE Healthcare and Insightec announced U.S. Food and Drug Administration (FDA) approval and CE mark for Insightec’s...
Delta T1 Maps Provide Quantitative, Automated Solution to Assess Brain Tumor Burden
News | Neuro Imaging | July 05, 2019
Imaging Biometrics LLC (IB) a subsidiary of IQ-AI Ltd., is highlighting a recently published study in the American...